Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biotech licenses a China-developed anti-B7-H3 ADC.
Armed with $75m the company takes a risky asset into the clinic.
GEN1286 looks dead, though MCLA-129 continues for now.
